Multiplicity of experimental approaches to therapy for genetic muscle diseases and necessity for population screening

Journal of Muscle Research and Cell Motility

Volumn 29, Issue 6-8, 2008, Pages 247-252

  Laing, Nigel G ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Experimental treatments; Genetic muscle diseases; Newborn screening; Prevention; Therapy

Indexed keywords

ADAM PROTEIN; AGRIN; CALPASTATIN; DEFLAZACORT; DYSTROPHIN; HISTONE DEACETYLASE INHIBITOR; IDEBENONE; INSULIN GROWTH FACTOR 1; INTEGRIN; MYOSTATIN; PREDNISOLONE; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN ADAM12; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UTROPHIN;

CELL THERAPY; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; HUMAN; MASS SCREENING; MUSCLE DISEASE; NONSENSE MUTATION; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENETIC DISEASES, INBORN; GENETIC TESTING; HUMANS; MUSCULAR DISEASES; POPULATION;

EID: 62449317807     PISSN: 01424319     EISSN: 15732657     Source Type: Journal    
DOI: 10.1007/s10974-008-9158-5     Document Type: Review

References (62)

1. H Amthor R Macharia R Navarrete 2007 Lack of myostatin results in excessive muscle growth but impaired force generation Proc Natl Acad Sci USA 104 1835 1840 10.1073/pnas.0604893104
2. V Arechavala-Gomeza IR Graham LJ Popplewell 2007 Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle Hum Gene Ther 18 798 810 10.1089/hum.2006.061
3. S Assereto S Stringara F Sotgia 2006 Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment Am J Physiol Cell Physiol 290 C577 C582 10.1152/ajpcell.00434.2005
4. M Bartoli E Gicquel L Barrault 2008 Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation Hum Mol Genet 17 1214 1221 10.1093/hmg/ddn029
5. R Beckmann M Sauer U-P Ketelsen 1978 Early diagnosis of Duchenne muscular dystrophy Lancet ii 105 10.1016/S0140-6736(78)91419-8
6. BF Benabdallah M Bouchentouf J Rousseau 2008 Inhibiting myostatin with follistatin improves the success of myoblast transplantation in dystrophic mice Cell Transplant 17 337 350
7. S Bhagavati 2008 Stem cell based therapy for skeletal muscle diseases Curr Stem Cell Res Ther 3 219 228 10.2174/157488808785740343
8. S Bogdanovich EM McNally TS Khurana 2008 Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C Muscle Nerve 37 308 316 10.1002/mus.20920
9. MD Bonifati G Ruzza P Bonometto 2000 A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy Muscle Nerve 23 1344 1347 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3. 0.CO;2-F
10. M Bouchentouf BF Benabdallah P Bigey 2008 Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles Gene Ther 15 404 414 10.1038/sj.gt.3303059
11. DM Bradley EP Parsons AJ Clarke 1993 Experience with screening newborns for Duchenne muscular dystrophy in Wales BMJ 306 357 360
12. DJ Burkin GQ Wallace KJ Nicol 2001 Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice J Cell Biol 152 1207 1218 10.1083/jcb.152.6.1207
13. KM Bushby A Hill JG Steele 1999 Failure of early diagnosis in symptomatic Duchenne muscular dystrophy Lancet 353 557 558 10.1016/S0140-6736(98)05279-9 (letter)
14. Buyse GM, Van der Mieren G, Erb M, et al. (2008) Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J
15. G Camirand L Stephan J Rousseau 2008 Central tolerance to myogenic cell transplants does not include muscle neoantigens Transplantation 85 1791 1801
16. M Cerletti T Negri F Cozzi 2003 Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer Gene Ther 10 750 757 10.1038/sj.gt.3301941
17. M Cerletti S Jurga CA Witczak 2008 Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles Cell 134 37 47 10.1016/j.cell.2008.05.049
18. JR Deol G Danialou N Larochelle 2007 Successful compensation for dystrophin deficiency by a helper-dependent adenovirus expressing full-length utrophin Mol Ther 15 1767 1774 10.1038/sj.mt.6300260
19. V Dubowitz 2002 Therapeutic possibilities in muscular dystrophy: the hope versus the hype Neuromuscul Disord 12 113 116 10.1016/S0960-8966(01)00319-4
20. M Eagle SV Baudouin C Chandler 2002 Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation Neuromuscul Disord 12 926 929 10.1016/S0960-8966(02)00140- 2
21. A Ferrer H Foster KE Wells 2004 Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins Gene Ther 11 884 893 10.1038/sj.gt.3302242
22. D Gardner-Medwin S Bundey S Green 1978 Early diagnosis of Duchenne muscular dystrophy Lancet 1 1102 10.1016/S0140-6736(78)90949-2
23. P Gregorevic MJ Blankinship JM Allen 2008 Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice Mol Ther 16 657 664 10.1038/mt.2008.28
24. MD Grounds HG Radley BL Gebski MA Bogoyevitch T Shavlakadze 2008 Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle Clin Exp Pharm Physiol 35 846 851
25. JBS Haldane 1935 The rate of spontaneous mutation of a human gene J Genet 31 317 326 10.1007/BF02982403
26. H Herweijer JA Wolff 2007 Gene therapy progress and prospects: hydrodynamic gene delivery Gene Ther 14 99 107
27. EP Hoffman RH Brown LM Kunkel 1987 Dystrophin: the protein product of the Duchenne muscular dystrophy locus Cell 51 919 928 10.1016/0092-8674(87)90579-4
28. C Holding D Bentley R Roberts 1993 Development and validation of laboratory procedures for preimplantation diagnosis of Duchenne muscular dystrophy J Med Genet 30 903 909 10.1136/jmg.30.11.903
29. J Huard R Roy JP Bouchard 1992 Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions Transplant Proc 24 3049 3051
30. BA Kakulas 1997 Problems and potential for gene therapy in Duchenne muscular dystrophy Neuromuscul Disord 7 319 324 10.1016/S0960-8966(97)00056-4
31. RM Kapsa SH Wong AF Quigley 2008 Electroporation of corrective nucleic acids (CNA) in vivo to promote gene correction in dystrophic muscle Methods Mol Biol 423 405 419 (Clifton, NJ)
32. M Koenig EP Hoffman CJ Bertelson 1987 Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals Cell 50 509 517 10.1016/0092-8674(87) 90504-6
33. CS Kuhr M Lupu R Storb 2007 Hematopoietic cell transplantation directly into dystrophic muscle fails to reconstitute satellite cells and myofibers Biol Blood Marrow Transplant 13 886 888 10.1016/j.bbmt.2007.04.012
34. LM Kunkel E Bachrach RR Bennett 2006 Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish J Hum Genet 51 397 406 10.1007/s10038-006-0374-9
35. Y Lai Y Yue M Liu 2005 Efficient in vivo gene expression by trans-splicing Adeno-associated viral vectors Nat Biotechnol 23 1435 1439 10.1038/nbt1153
36. NG Laing 1993
37. Manzur AY, Kuntzer T, Pike M et al (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane database of systematic reviews (Online):CD003725
38. ER Mardis 2006 Anticipating the 1,000 dollar genome Genome Biol 7 112 10.1186/gb-2006-7-7-112
39. GC Minetti C Colussi R Adami 2006 Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors Nat Med 12 1147 1150 10.1038/nm1479
40. B Moghadaszadeh R Albrechtsen LT Guo 2003 Compensation for dystrophin-deficiency: ADAM12 overexpression in skeletal muscle results in increased alpha 7 integrin, utrophin and associated glycoproteins Hum Mol Genet 12 2467 2479 10.1093/hmg/ddg264
41. J Moll P Barzaghi S Lin 2001 An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy Nature 413 302 307 10.1038/35095054
42. B Muller C Dechant G Meng 1992 Estimation of the male and female mutation rates in Duchenne muscular dystrophy (DMD) Hum Genet 89 204 206
43. GL Odom P Gregorevic JM Allen 2008 Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice Mol Ther 16 1539 1545 10.1038/mt.2008.149
44. EP Parsons AJ Clarke K Hood 2002 Newborn screening for Duchenne muscular dystrophy: a psychosocial study Arch Dis Child 86 F91 F95 10.1136/adc.86.2.91
45. EP Parsons DM Bradley AJ Clarke 2003 Newborn screening for Duchenne muscular dystrophy Arch Dis Child 88 91 92 10.1136/adc.88.1.91-b
46. EP Parsons AJ Clarke DM Bradley 2004 Developmental progress in Duchenne muscular dystrophy: lessons for earlier detection Eur J Paediatr Neurol 8 145 153 10.1016/j.ejpn.2004.01.009
47. EP Parsons JT King JA Israel 2007 Mothers' accounts of screening newborn babies in Wales (UK) Midwifery 23 59 65 10.1016/j.midw.2006.05.008
48. HG Radley MJ Davies MD Grounds 2008 Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment Neuromuscul Disord 18 227 238 10.1016/j.nmd.2007.11.002
49. JA Rafael JM Tinsley AC Potter 1998 Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice Nat Genet 19 79 82 10.1038/ng0598-79
50. JA Robertson 2003 The $1000 genome: ethical and legal issues in whole genome sequencing of individuals Am J Bioeth 3 W35 W42
51. AD Roses 1988 Mutants in Duchenne muscular dystrophy. Implications for prevention Arch Neurol 45 84 85
52. M Sampaolesi S Blot G D'Antona 2006 Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs Nature 444 574 579 10.1038/nature05282
53. T Shavlakadze J White JF Hoh 2004 Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice Mol Ther 10 829 843 10.1016/j.ymthe.2004.07.026
54. SD Silva-Barbosa GS Butler-Browne W de Mello 2008 Human myoblast engraftment is improved in laminin-enriched microenvironment Transplantation 85 566 575
55. MJ Spencer RL Mellgren 2002 Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology Hum Mol Genet 11 2645 2655 10.1093/hmg/11.21.2645
56. JM Tinsley AC Potter SR Phelps 1996 Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene Nature 384 349 353 10.1038/384349a0
57. JC van Deutekom AA Janson IB Ginjaar 2007 Local dystrophin restoration with antisense oligonucleotide PRO051 N Engl J Med 357 2677 2686 10.1056/NEJMoa073108
58. KR Wagner JL Fleckenstein AA Amato 2008 A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy Ann Neurol 63 561 571 10.1002/ana.21338
59. EM Welch ER Barton J Zhuo 2007 PTC124 targets genetic disorders caused by nonsense mutations Nature 447 87 91 10.1038/nature05756
60. DJ Wells 2006 Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy J Muscle Res Cell Motil 27 387 398 10.1007/s10974-006-9081-6
61. S Wilton 2007 PTC124, nonsense mutations and Duchenne muscular dystrophy Neuromuscul Disord 17 719 720 10.1016/j.nmd.2007.07.001
62. Y Yue A Ghosh C Long B Bostick BF Smith JN Kornegay D Duan 2008 A single intravenous injection of Adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs Mol Ther 16 1944 1952